• Join
  • Login
  • Contact

Search abstracts / presentations

In vitro release of novel dosage forms

  • In: C7 - Dissolution: The pivotal tool for developing quality drugs on Thursday, 8 September 2011, 09:00-12:00
  • At: Hyderabad (India) (2011)
  • Type: Presentation
  • By: FRIEDEL, Horst-Dieter (Bayer Healthcare Pharmaceuticals, Berlin, Germany)
  • Co-author(s): Brown, CK (Eli Lilly and Company, Indianapolis, United States of America)
    Barker, AR (Eli Lilly and Company, Indianapolis, United States of America)
    Buhse, LF (Food and Drug Administration/CDER/OPS, St. Louis, United States of America)
    Keitel, S (EDQM, Strasbourg, France)
    Cecil, TL (United States Pharmacopoeia, Rockville, United States of America)
    Kraemer, J (PHAST, Homburg, Germany)
    Morris, JM (Irish Medicines Board, Dublin, Ireland)
    Reppas, C (National & Kapodistrian University of Athens, Panepistimiopolis, Greece)
    Stickelmeyer, MP (Eli Lilly and Company, Indianapolis, United States of America)
    Yomota, C (National Institute of Health Science, Tokyo, Japan)
    Shah, VP (FIP Scientific Secretary, The Hague, Netherlands)
  • Abstract:

    Although dissolution testing was initially developed for solid oral dosage forms, the application of dissolution testing has expanded to a variety of "novel" or "special" dosage forms. Analogous to the dissolution test for solid oral dosage forms the drug release test of novel dosage forms is used for the biopharmaceutical characterization of the


  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses